Pharmaron Beijing Co., Ltd.
300759
Kedudukan dalam Saham
#2354
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a... Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Harga Saham
$5.58
Modal Pasaran
$8.24B
Perubahan (1 hari)
-3.77%
Perubahan (1 tahun)
28.36%
Negara
CN
Perdagangan Pharmaron Beijing Co., Ltd. (300759)
Kategori
Healthcare
Nisbah P/E bagi Pharmaron Beijing Co., Ltd. (300759)
Nisbah P/E pada October 2026 TTM: 38.39
Menurut laporan kewangan dan harga saham terkini Pharmaron Beijing Co., Ltd., nisbah P/E semasa (TTM) ialah 38.39. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak 25.36.
Sejarah nisbah P/E bagi Pharmaron Beijing Co., Ltd. dari 2014 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | 38.39 | 26.96% |
| 2025 | 30.24 | 19.25% |
| 2024 | 25.36 | -21.07% |
| 2023 | 32.13 | -45.04% |
| 2022 | 58.47 | 95.59% |
| 2021 | 29.89 | -17.12% |
| 2020 | 36.07 | 31.24% |
| 2019 | 27.48 | 204.91% |
| 2018 | 9.01 | -52.17% |
| 2017 | 18.85 | -10.26% |
| 2016 | 21.00 | -37.39% |
| 2015 | 33.54 | -71.57% |
| 2014 | 117.97 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 30.83 | -19.69% |
US
|
|
| -29.16 | -175.96% |
US
|
|
| -25.99 | -167.70% |
AU
|
|
| 22.43 | -41.57% |
BE
|
|
| 31.22 | -18.69% |
NL
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.